VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives Average Rating of “Reduce” from Brokerages

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has received a consensus rating of “Reduce” from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $0.95.

Several brokerages have recently commented on VTGN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, October 8th. Stifel Nicolaus lowered VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 target price for the company. in a research report on Wednesday. William Blair downgraded VistaGen Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday. Maxim Group lowered VistaGen Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Jefferies Financial Group downgraded shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $0.90 price objective for the company. in a report on Wednesday.

VistaGen Therapeutics Trading Down 80.2%

VTGN stock traded down $3.50 during trading on Wednesday, reaching $0.86. The stock had a trading volume of 67,064,685 shares, compared to its average volume of 657,980. VistaGen Therapeutics has a 1-year low of $0.75 and a 1-year high of $5.14. The company has a market capitalization of $34.04 million, a P/E ratio of -0.47 and a beta of 0.56. The firm has a fifty day moving average price of $4.20 and a 200 day moving average price of $3.32.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The company had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.16 million. Sell-side analysts predict that VistaGen Therapeutics will post -1.77 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC raised its holdings in VistaGen Therapeutics by 246.4% during the first quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company’s stock worth $1,052,000 after purchasing an additional 299,304 shares in the last quarter. Two Sigma Investments LP raised its stake in shares of VistaGen Therapeutics by 223.5% in the 3rd quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock worth $1,027,000 after buying an additional 199,958 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of VistaGen Therapeutics in the second quarter valued at $190,000. Stempoint Capital LP lifted its holdings in shares of VistaGen Therapeutics by 2.0% in the second quarter. Stempoint Capital LP now owns 2,413,254 shares of the company’s stock valued at $4,827,000 after buying an additional 46,700 shares during the period. Finally, AdvisorShares Investments LLC boosted its stake in VistaGen Therapeutics by 27.7% during the second quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company’s stock valued at $406,000 after buying an additional 44,000 shares in the last quarter. 78.39% of the stock is currently owned by institutional investors.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.